These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 10806996)

  • 1. Two problems in antisense biotechnology: in vitro delivery and the design of antisense experiments.
    Stein CA
    Biochim Biophys Acta; 1999 Dec; 1489(1):45-52. PubMed ID: 10806996
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Application of antisense technology to therapeutics.
    Heidenreich O; Kang SH; Xu X; Nerenberg M
    Mol Med Today; 1995 Jun; 1(3):128-33. PubMed ID: 9415148
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design and application of antisense oligonucleotides in cell culture, in vivo, and as therapeutic agents.
    Brysch W; Schlingensiepen KH
    Cell Mol Neurobiol; 1994 Oct; 14(5):557-68. PubMed ID: 7621513
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Does antisense exist?
    Stein CA
    Nat Med; 1995 Nov; 1(11):1119-21. PubMed ID: 7584974
    [No Abstract]   [Full Text] [Related]  

  • 5. Intracellular delivery strategies for antisense phosphorodiamidate morpholino oligomers.
    Ghosh C; Iversen PL
    Antisense Nucleic Acid Drug Dev; 2000 Aug; 10(4):263-74. PubMed ID: 10984120
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Locked nucleic acid: a potent nucleic acid analog in therapeutics and biotechnology.
    Jepsen JS; Sørensen MD; Wengel J
    Oligonucleotides; 2004; 14(2):130-46. PubMed ID: 15294076
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phosphorothioate antisense oligonucleotides induce the formation of nuclear bodies.
    Lorenz P; Baker BF; Bennett CF; Spector DL
    Mol Biol Cell; 1998 May; 9(5):1007-23. PubMed ID: 9571236
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antisense oligonucleotides: target validation and development of systemically delivered therapeutic nanoparticles.
    Zhang C; Pei J; Kumar D; Sakabe I; Boudreau HE; Gokhale PC; Kasid UN
    Methods Mol Biol; 2007; 361():163-85. PubMed ID: 17172711
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cationic lipids, phosphatidylethanolamine and the intracellular delivery of polymeric, nucleic acid-based drugs (review).
    Hope MJ; Mui B; Ansell S; Ahkong QF
    Mol Membr Biol; 1998; 15(1):1-14. PubMed ID: 9595549
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enhanced antisense efficacy of oligonucleotides adsorbed to monomethylaminoethylmethacrylate methylmethacrylate copolymer nanoparticles.
    Zobel HP; Junghans M; Maienschein V; Werner D; Gilbert M; Zimmermann H; Noe C; Kreuter J; Zimmer A
    Eur J Pharm Biopharm; 2000 May; 49(3):203-10. PubMed ID: 10799810
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Factors determining the efficacy of nuclear delivery of antisense oligonucleotides by gold nanoparticles.
    Liu Y; Franzen S
    Bioconjug Chem; 2008 May; 19(5):1009-16. PubMed ID: 18393455
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antisense has growing pains.
    Gura T
    Science; 1995 Oct; 270(5236):575-7. PubMed ID: 7570012
    [No Abstract]   [Full Text] [Related]  

  • 13. Inhibition of troponin C production without affecting other muscle protein synthesis by the antisense oligodeoxynucleotide.
    Ojala J; Choudhury M; Bag J
    Antisense Nucleic Acid Drug Dev; 1997 Feb; 7(1):31-8. PubMed ID: 9055036
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antisense effects in the cell nucleus: modification of splicing.
    Kole R; Sazani P
    Curr Opin Mol Ther; 2001 Jun; 3(3):229-34. PubMed ID: 11497345
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effective intracellular delivery of oligonucleotides in order to make sense of antisense.
    Shi F; Hoekstra D
    J Control Release; 2004 Jun; 97(2):189-209. PubMed ID: 15196747
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Structural requirements for cationic lipid mediated phosphorothioate oligonucleotides delivery to cells in culture.
    Bennett CF; Mirejovsky D; Crooke RM; Tsai YJ; Felgner J; Sridhar CN; Wheeler CJ; Felgner PL
    J Drug Target; 1998; 5(3):149-62. PubMed ID: 9606005
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nuclear antisense effects of neutral, anionic and cationic oligonucleotide analogs.
    Sazani P; Kang SH; Maier MA; Wei C; Dillman J; Summerton J; Manoharan M; Kole R
    Nucleic Acids Res; 2001 Oct; 29(19):3965-74. PubMed ID: 11574678
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Morpholino antisense oligomers: the case for an RNase H-independent structural type.
    Summerton J
    Biochim Biophys Acta; 1999 Dec; 1489(1):141-58. PubMed ID: 10807004
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oligonucleotide analogs might be designed to bind to m-RNA.
    Crooke ST
    Anticancer Drug Des; 1997 Jul; 12(5):311-3. PubMed ID: 9236848
    [No Abstract]   [Full Text] [Related]  

  • 20. [Current status of antisense drugs].
    Li XJ
    Sheng Li Ke Xue Jin Zhan; 2000 Apr; 31(2):115-9. PubMed ID: 12545727
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.